Home Tags Akcea

Akcea

NICE Refused Waylivra as Familial Chylomicronaemia Syndrome Treatment

The National Institute for Health and Care Excellence (NICE) has issued an Evaluation Consultation Document (ECD), refusing Waylivra (volanesorsen) as a treatment for Familial...

Pfizer Agreed to Pay $250m as Part of Licensing Deal with Ionis Pharmaceuticals

Pfizer agreed to pay $250 million upfront as part of a licensing deal with Ionis Pharmaceuticals and its majority-owned affiliate Akcea Therapeutics to develop...

NICE Published Final Guideline for Akcea Nerve Damage Drug

Akcea Therapeutics UK has announced that the National Institute for Health and Care Excellence (NICE) has published a final guideline for its nerve damage...

EMA Recommended First Med for FCS

The European Medicines Agency has recommended granting a conditional marketing authorisation (CMA) for Waylivra (volanesorsen), the first medicine for the treatment of the familial...

Novartis to Get Rights of Ionis’ CVD Treatment

Novartis announced today that it is exercising its option to license the rights to develop and commercialize TQJ230, an investigational agent previously known as...
20,104FansLike
2,236FollowersFollow
2,275SubscribersSubscribe

Hot Topics

Marken Will Double the Space of its GMP Facility in Frankfurt

Marken announced it will double the space of its GMP facility in Frankfurt to further expand its frozen room storage capabilities in anticipation of...

Brazil Tests Coronavirus Vaccine from Chinese Company Sinovac in Six States

A potential coronavirus vaccine developed by China’s Sinovac will be tested in Brazil by 12 research centers in six Brazilian states, the governor of...

China’s First Coronavirus mRNA Vaccine Approved for Clinical Trials

ARCoV, a novel coronavirus Messenger RNA (mRNA) vaccine candidate jointly developed by the People's Liberation Army (PLA) Academy of Military Sciences, Suzhou Abogen Biosciences...